The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery
Open accessAbstract
PurposeTo formulate rifampicin, an anti-tuberculosis antibiotic, for aerosol delivery in a dry powder ‘porous nanoparticle-aggregate particle’ (PNAP) form suited for shelf stability, effective dispersibility and extended release with local lung and systemic drug delivery.MethodsRifampicin was encapsulated in PLGA nanoparticles by a solvent evaporation process, spray dried into PNAPs containing varying amounts of nanoparticles, and characterized for physical and aerosol properties. Pharmacokinetic studies were performed with formulations delivered to guinea pigs by intratracheal insufflation and compared to oral and intravenous delivery of rifampicin.ResultsThe PNAP formulations possessed properties suitable for efficient deposition in the lungs. In vitro release showed an initial burst of rifampicin, with the remainder available for release beyond eight hours. PNAPs delivered to guinea pigs by insufflation achieved systemic levels of rifampicin detected for six to eight hours. Moreover, rifampicin concentrations remained detectable in lung tissue and cells up to and beyond eight hours. Conversely, after pulmonary delivery of an aerosol without nanoparticles, rifampicin could not be detected in the lungs at eight hours.ConclusionsOur results indicate that rifampicin can be formulated into an aggregated nanoparticle form that, once delivered to animals, achieves systemic exposure and extends levels of drug in the lungs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324 · cited 1×
“Nanoparticle formulations are a particularly interesting approach to sustained delivery in the lungs given the avid uptake of nanoparticles by macrophages and other cells of the immune system (13, 14 ).”
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
RILEY, R. L., MILLS, C. C., NYKA, W., WEINSTOCK, N., STOREY, P. B., SULTAN, L. U., RILEY, M. C., & WELLS, W. F. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117542 · Cited by 269 · cited 1×
“tuberculosis (2) and subsequent uptake of the bacterium by alveolar macrophages (3).”
Single dose and multiple dose studies of itraconazole nanoparticles
Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., & Williams, R. O. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.01.006 · Cited by 85
Cited by
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Ahmed, T., & Aljaeid, B. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s99651 · Cited by 705
Sosnik, A., & Seremeta, K. P. (2015) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2015.05.003 · Cited by 671
Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels
Korin, N., Kanapathipillai, M., Matthews, B. D., Crescente, M., Brill, A., Mammoto, T., Ghosh, K., Jurek, S., Bencherif, S. A., Bhatta, D., et al. (2012) · Science · doi:10.1126/science.1217815 · Cited by 540
Current applications of nanoparticles in infectious diseases
Zazo, H., Colino, C. I., & Lanao, J. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.008 · Cited by 434
Metadata
- Authors
- Sung, J. C., Padilla, D. J., Garcia-Contreras, L., VerBerkmoes, J. L., Durbin, D., Peloquin, C. A., Elbert, K. J., Hickey, A. J., & Edwards, D. A.
- Venue
- Pharmaceutical Research
- Published
- 2009-04-30
- Volume
- 26
- Issue
- 8
- Pages
- 1847-1855
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1969474451
- Cited by
- 244
- References
- 4
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.